Guidance

Exceptions and modifications to the EU guidance on good pharmacovigilance practices that will apply in a no-deal Brexit

This guidance clarifies the expectations on the application of the EU guidance on good pharmacovigilance practices (GVP) in a no-deal Brexit.

From:
Medicines and Healthcare products Regulatory Agency
Published
26 September 2019
Last updated
9 October 2019 — See all updates

This publication was withdrawn on

For updated information on good pharmacovigilance practices see Exceptions and modifications to the EU guidance on good pharmacovigilance practices that apply to UK MAHs and the MHRA.

Documents

GVP guidance note

PDF, 637 KB, 71 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

GVP are a set of measures drawn up to facilitate the performance of pharmacovigilance in the EU. GVP apply to marketing authorisation holders (MAHs), the European Medicines Agency and medicines regulatory authorities in EU member states. They cover medicines authorised centrally through the EMA as well as medicines authorised at national level.

This guidance describes the aspects of the EU guidance on GVP that will no longer apply to the MHRA and UK MAHs or are to be read subject to modification in a no-deal Brexit.

Published 26 September 2019
Last updated 9 October 2019 + show all updates

  1. Change of text within Stay up to date box.

  2. First published.